| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_92e4d0157c96683dc1929497ebdb5e95
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5f2bf69648809a4c37aa77b7b8c64e0a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0c3574f6f059899b268c88dde6164257
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_780a950771ef2edaae8a749252a8c14d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7e8d2afa63dbd8bbb90545722d3f54c1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_079a5b3eecbeb0e5fcc2e9b817b28c97 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-353
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5517 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-353
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate |
2009-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57dfddeab708b80f00b8ca37c4163fa9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea18f219a274e906321c679c424c3898
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25f8b12f1abfc05580d1e4936bdb1289
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42839c21b65c982ff726a82a65483e72 |
| publicationDate |
2010-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2010074480-A3 |
| titleOfInvention |
Novel pyrazolodiazepine compounds as a transglutaminase inhibitor, the preparation method thereof and a composition containing the same |
| abstract |
The present invention relates to the novel pyrazolodiazepine compounds which potently inhibit the activity of transglutaminase in a dose dependent manner. Accordingly, it has been confirmed that the inventive compounds show potent inhibiting effect on the hyper- activated transglutaminase when the transglutaminase is over-expressed. Therefore the compounds can be useful in treating or preventing the disease caused by increased activation of transglutaminase. |
| priorityDate |
2008-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |